The Benefits and Challenges of the Multimodal Treatment in Advanced/Metastatic Malignant Melanoma.
adverse events
chemotherapy
malignant melanoma
new therapeutic approach
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
05 May 2023
05 May 2023
Historique:
received:
15
03
2023
revised:
02
05
2023
accepted:
03
05
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Currently, the treatment of malignant melanoma offers the longest and the most studied experience of innovative treatments in malignant pathology. The algorithm of the therapeutic decision in advanced or metastatic melanoma must comprise: the timing of the therapeutic initiation, the sequencing of the specific oncological treatment (radiotherapy and chemotherapy still being therapeutic alternatives in selected cases), the diagnosis and the management of adverse reactions. We present the case of a patient diagnosed with metastatic malignant melanoma in November 2019, who progressed successively under new systemic treatment throughout the 3 years of treatment and experienced skin reactions of various degrees of severity. The comprehensive response to secondary hilar pulmonary lymphatic determinations under subsequent chemotherapy was specific to the presented case. The occurrence of vitiligo secondary to immunotherapy is a favorable prognostic factor, but the occurrence of secondary cerebral determinations is an extremely severe prognostic factor in malignant melanoma and a challenge in making the therapeutic decision. Previous treatment with immune checkpoint inhibitors may trigger a favorable response to systemic chemotherapy. The early and accurate diagnosis of the adverse events of the new therapies requires a multidisciplinary approach, because it can radically change the therapeutic decision.
Identifiants
pubmed: 37175025
pii: diagnostics13091635
doi: 10.3390/diagnostics13091635
pmc: PMC10178057
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
Eur J Cancer. 2021 Sep;155:268-280
pubmed: 34392069
Oncotarget. 2018 Sep 28;9(76):34336-34346
pubmed: 30344946
Ann Oncol. 2019 Feb 1;30(2):219-235
pubmed: 30608567
J Skin Cancer. 2020 Nov 05;2020:7520924
pubmed: 33282420
Radiographics. 2016 Sep-Oct;36(5):1463-77
pubmed: 27541436
J Immunol. 2012 Oct 15;189(8):3789-93
pubmed: 23042723
J Skin Cancer. 2011;2011:423239
pubmed: 22175026
Diagnostics (Basel). 2021 Jun 18;11(6):
pubmed: 34207125
Cancers (Basel). 2023 Jan 30;15(3):
pubmed: 36765822
Lung Cancer Manag. 2019 May 09;4(6):LMT12
pubmed: 31645892
J Clin Imaging Sci. 2017 Oct 03;7:38
pubmed: 29114437
Ther Adv Med Oncol. 2016 Jan;8(1):48-56
pubmed: 26753005
P T. 2012 Sep;37(9):503-30
pubmed: 23066344
Curr Oncol. 2022 Oct 02;29(10):7388-7395
pubmed: 36290857
Diagnostics (Basel). 2023 Mar 06;13(5):
pubmed: 36900146
J Clin Oncol. 2013 Feb 1;31(4):482-9
pubmed: 23248257
Expert Opin Drug Saf. 2021 Aug;20(8):883-888
pubmed: 33896329
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):607-614
pubmed: 32846030
J Natl Cancer Inst. 2021 Nov 29;113(12):1648-1669
pubmed: 34240195
Life (Basel). 2022 Aug 29;12(9):
pubmed: 36143375
Int J Mol Sci. 2022 Mar 27;23(7):
pubmed: 35409020
Medicine (Baltimore). 2017 Oct;96(43):e8293
pubmed: 29068998
Lancet Reg Health Eur. 2021 Jan 06;2:100024
pubmed: 34557790
Eur J Cancer. 2022 Feb;162:22-33
pubmed: 34952480
Melanoma Res. 2012 Apr;22(2):114-22
pubmed: 22395415
Cancers (Basel). 2022 Jul 22;14(15):
pubmed: 35892846
Am Soc Clin Oncol Educ Book. 2018 May 23;38:741-750
pubmed: 30231345
Cell Mol Life Sci. 2022 Mar 16;79(3):191
pubmed: 35292881
Cancer Manag Res. 2014 Jun 20;6:279-89
pubmed: 25018651
ESMO Open. 2021 Apr;6(2):100064
pubmed: 33711672
J Am Acad Dermatol. 2022 Mar;86(3):515-524
pubmed: 34915056